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The microbial resistance to antibiotics is a genuine global threat. Consequently, a search of new inhibitors
remains of acute importance due to the increasing spread of multidrug resistance. Here we present a new
type of non-b-lactam b-lactamase inhibitor PA-34 based on natural phenoxyaniline, identiﬁed using
computer-assisted screening of scaffolds related to those of known low-afﬁnity inhibitors. The com-
pound displays reversible competitive inhibition of bacterial b-lactamase TEM-171, with a Ki of 88 mM.
Using enzyme kinetics, infra-red spectroscopy, ﬂuorescence quenching and computer docking, we pro-
pose that the inhibitor binds at the entrance to the enzyme active site. This is a novel inhibition
mechanism compared to binding covalently to the catalytic serine in the active site or non-covalently to
the allosteric site. The residues involved in binding the inhibitor are conserved among molecular class A
b-lactamases. The identiﬁed compound and its proposed binding mode may have a potential for a
regulation of the catalytic activity of a wide range of class A b-lactamases. We also hypothesise that the
presented route for ﬁnding non-b-lactam compounds may be an effective and durable approach for
combating bacterial antibiotic resistance.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Since the discovery of penicillin by Alexander Fleming and its
introduction into general medical practice in the 1940s, b-lactam
compounds have become one of the three largest classes of anti-
biotics [1]. They comprise more than half of the antibiotics used
worldwide for the treatment of a variety of infectious diseases [2].
These antibiotics represent a broad class of polar hydrophilic
compounds containing a b-lactam ring. They act by inhibiting the
synthesis of the peptidoglycan layer of the bacterial cell wall,
thereby impairing the structural integrity of the cell [3]. Subse-
quent drug discovery and development has produced more b-lac-
tam antibiotics, which are, at present, divided into four groups
based on their chemical structures: penicillins, cephalosporins,
carbapenems and monobactams (Table S1). The driving force
behind the search for new antibiotics is the continual ability of
bacteria to adapt to earlier and existing generations of antibioticsþ7 4959392742.
. Grigorenko).
r B.V. This is an open access articlethrough a development of resistance mechanisms. This antibiotic
resistance, creating a major, widespread problem, has been realised
for more than 40 years [4] and has become a serious and growing
threat to public health [2,5,6].
The most prevalent resistance mechanism in Gram-negative
bacteria is the production of b-lactamase enzymes, which inacti-
vate the antibiotic by hydrolysing the b-lactam ring [7]. The serine
b-lactamases of the molecular classes A, C, and D hydrolyse the b-
lactam ring by forming a covalent acyl-intermediate to the catalytic
serine in the enzyme active site. The metallo-b-lactamases of mo-
lecular class B additionally require one or two zinc ions, and their
catalysis proceeds via a transition state involving a zinc-stabilised
hydroxide ion [8]. Most attention has recently been attracted by
the problem of plasmid-encoded extended spectrum b-lactamases
(ESBLs) [9,10]. The term ESBL was initially used to designate the
mutant forms of TEM- and SHV-type b-lactamases that are able to
hydrolyse oxyimino-cephalosporins, but now it also concerns CTX-
M, OXA, AmpC, VEB and other types of b-lactamases [11,12]. The
number of described unique b-lactamases obtained from clinical
isolates is estimated to be at least 1300 [11]. This poses a signiﬁcant
threat to the efﬁcacy of b-lactam antibiotics.under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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is the driving force for the increasing rates of resistance [13]. As the
resistance of bacteria to antibiotics develops indeed rapidly, drug
development in addition to a search for new antibiotics is hunting for
ways to inhibit b-lactamases. Such inhibitors proved efﬁcient; they
target the active site of the enzyme and are co-administered with b-
lactam antibiotics e the examples include clavulanic acid with
amoxicillin or sulbactamwith ampicillin (Fig. S1). However, since the
currently used b-lactamase inhibitors contain the b-lactam ring, they
are as susceptible to time-limited application as the antibiotics
themselves. In addition, the active site of b-lactamases is susceptible
to mutations that circumvent the binding of b-lactamase inhibitors;
inhibitor-resistant b-lactamases (IRTs) have developed over time,
even those that confer resistance to all the marketed b-lactamase
inhibitors [14] while preserving the ability to cleave the antibiotics.
Dissemination of multiple drug resistance further complicates the
task of inactivating b-lactamases and emphasises the importance of
developing novel b-lactamase inhibitorswith extended lifetimes [15].
Promising approaches involve the development of non-b-lactam
inhibitors, which can be active against a wide range of different b-
lactamases. Several inhibitors have already been described [15e17].
These include diazabicyclooctanes (avibactam and MK-7655) and
derivatives of boronic acid that are active against class A, C and D b-
lactamases. Another type of inhibitor, FTA, 3-(4-Phenylamino-phe-
nylamino)-2-(1H-tetrazol-5-yl)-acrylonitrile, was described and
shown to bind to the allosteric site, distinct from the active site of the
enzyme [18,19]. Targeting a less frequently mutating area of the
enzyme with a widely applicable inhibitor seems, therefore, an
intriguing approach to drug design in theﬁeld of antibiotic resistance.
The aim of this study was to design a novel non-b-lactam in-
hibitor, preferably targeting a different binding site of a b-lacta-
mase. Here, we report the synthesis and characterisation of an
acylated phenoxyaniline compound, hereafter called PA-34, as a
novel type of a non-b-lactam inhibitor. We used recombinant b-
lactamase TEM-171 as a model enzyme of class A b-lactamases,
which has comparable catalytic parameters to the wild-type b-
lactamase TEM-1 [20]. Enzyme-inhibitor interactions were
modelled in a molecular docking study and experimentally probed
by IR-spectroscopy and ﬂuorescence quenching studies.
2. Materials and methods
2.1. Reagents
The reagents were purchased from Sigma-Aldrich (http://www.
sigmaaldrich.com) and Difco (http://www.bd.com) and used
without further puriﬁcation. Enzymes for DNA ampliﬁcation, re-
striction and modiﬁcation were purchased from Stratagene (http://
www.agilent.com), New England Biolabs (https://www.neb.com/)
and Thermo Fisher Scientiﬁc (https://www.thermoﬁsher.com). Oli-
gonucleotides for sequencing and PCR were purchased from Syntol
(http://www.syntol.ru). The plasmid vectors pET-20 and pET-24a(þ)
and E.coli strains DH5a and BL21(DE3) were purchased from
Novagen (http://www.merckmillipore.com). The preparative work
with DNAwas performed using a Qiagen QIAprep Spin Miniprep Kit
and a Qiagen QIAquick Gel Extraction Kit (http://www.qiagen.com).
Protein electrophoresis (SDS-PAGE) was performed according to
Laemmli [21], using a Thermo Fisher Scientiﬁc lowmolecular weight
protein kit (SM0431) as the molecular weight standards. Protein
concentration was measured with Sigma-Aldrich BCA test kit.
2.2. DNA manipulation and generation of b-lactamase expression
strain
DNA techniques, such as plasmid isolation, transformation ofE.coli, ligations and restriction analysis were standard methods.
E.coli strain DH5a was used for cloning and BL21(DE3) for protein
expression. The cells were cultivated in lysogeny broth (LB) me-
dium (0.5% yeast extract,1% peptone, 0.5% sodium chloride and 1.5%
bacto agar for solid medium) supplemented with 50 mg/l of
kanamycin.
To generate the recombinant b-lactamase TEM-171 over-
expression E. coli strain, the coding sequence of TEM-171, including
a periplasmic signal sequence (www.lahey.org/studies), was
ampliﬁed with Pfu DNA polymerase using b-lactamase TEM-171
encoding plasmid pET-20 as a template, 50-TTATATTAACATATG
CACCCAGAAACGCTGGTGAAAG-30 with NdeI site as the forward
primer and 50-TTTGCGGCCGCTCACCAATGCTTAATCAGTGAGGC-30
with NotI site as the reverse primer (restriction sites are under-
lined). The PCR product was transferred into the expression vector
pET-24a using NdeI/NotI. The resulting construct pET-bla was
veriﬁed by DNA sequencing and ﬁnally transformed into E. coli BL21
(DE3).
2.3. Expression and puriﬁcation of the recombinant class A b-
lactamase TEM-171
Cells were grown under vigorous shaking at 37 C in 300 mL LB
medium containing 50 mg/mL kanamycin. When the optical density
of the culture medium reached 0.6 (OD600) the expression was
induced by the addition of 0.1 mM isopropyl b-D-1-
thiogalactopyranoside (IPTG). The cells were further grown at
21 C for 50 h, harvested by centrifugation (3,600g, 15 min at 4 C)
and stored at 20 C before puriﬁcation. The periplasmic protein
fractionwas isolated using osmotic shock, by re-suspending the cell
pellet in 10 mM Tris/HCl, pH 8.0, containing 1 mM EDTA and 20%
(w/v) sucrose for 15 min at room temperature. Spheroplasts were
removed by centrifugation (10,000g, 10 min at 4 C) and the su-
pernatant containing the periplasmic fraction was dialysed against
10 mM Tris/HCl, pH 8.0. The crude extract was applied to a
SOURCE™ 15Q (10 cm  0.75 cm2) anion exchange column (http://
www.gehealthcare.com) and washed extensively with 10 mMTris/
HCl buffer, pH 8.0. The recombinant enzyme was eluted with a
linear salt gradient in the same buffer, containing about 80 mM
NaCl. Fractions containing b-lactamase TEM-171 were pooled and
dialysed against 10 mM Tris/HCl, pH 8.0 for 14e16 h at 4 C. The
protein was further puriﬁed by size exclusion chromatography
using a HiLoad 16/600 Superdex75 pg column (http://www.
gehealthcare.com) equilibrated with 10 mM Tris/HCl, pH 8.0. The
resulting enzyme-containing fractions were pooled and kept at 4 C
for further experiments. The purity of the enzyme was evaluated
using SDS-PAGE stained by Coomassie Brilliant Blue. Protein con-
centrations were determined using Sigma-Aldrich BCA test kit with
bovine serum albumin as a standard.
2.4. In silico search for new inhibitors
We used the novel ViCi software (www.embl-hamburg.de/vici)
for an in silico ligand-based drug design. In brief, as search tem-
plates we selected two known low-afﬁnity, non-b-lactam inhibitors
binding to b-lactamase TEM-1: FTA, 3-(4-phenylamino-phenyl-
amino)-2-(1H-tetrazol-5-yl)-acrylonitrile [18] and CBT, N,N-bis(4-
chlorobenzyl)-1H-1,2,3,4-tetraazol-5-amine [18], and two non-b-
lactam inhibitors binding to b-lactamase CTX-M-9: 1CE, 3-(1H-
tetrazol-5-ylmethyl)-5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyr-
imidin-4(3H)-one and F13, 3-ﬂuoro-N-[3-(1H-tetrazol-5-yl)
phenyl]benzamide [19]. These inhibitors were used as starting
points for screening the ViCi database for compounds of similar
shape and charge distribution ([22], Beshnova et al., manuscript in
preparation). The top 550 hits from the in silico screen were
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based on a microtiter plate format. The compounds were solubi-
lised in DMSO and the assay was performed in 20 ml of reaction
buffer with the addition of 0.1% BSA or 0.05% of the non-ionic
detergent pluronic F-127, and with concentrations of the enzyme,
screened compound and the substrate of 6.25 nM, 100 mM and
100 mM, respectively. The potency of the inhibitors was assessed
from the endpoint absorbance value at l ¼ 405 nm at a given time
point (a 30min linear reaction). The obtained datawere normalised
to the negative control (the same mixture without the inhibitor).
From this screen several compounds were identiﬁed showing
promising inhibitory effect on the b-lactamase TEM-171 activity.
From these, the PA-34 compound was chosen for the synthesis and
further investigation.2.5. Synthesis of PA-34 inhibitor
0.093 g of succinic acid anhydride was added to the solution of
0.216 g of 2,4-dichlorophenoxyaniline in 50 ml toluene. The
mixture was reﬂuxed for 12 h at 110 C and subsequently cooled to
room temperature. The resulting precipitate was ﬁltered out, dis-
solved in dichloromethane andwashed with a saturated solution of
ammonium chloride. The organic phase was dried with anhydrous
sodium sulphate. After the evaporation of the solvent, we obtained
0.201 g of phenoxyaniline as a white solid with a yield of 67%. The
reaction was monitored by thin layer chromatography (TLC) using
Merck TLC silica gel 60 F254 aluminium-backed precoated plates.
The plates were visualised by ultraviolet light at 254 nm. PA-34 was
characterised by 1H and 13C NMR, elemental analysis and mass
spectroscopy. NMR spectra were recorded using a Bruker 400 MHz
spectrometer. The 13C NMR spectra were measured with complete
proton decoupling. According to the NMR data, the obtained PA-34
inhibitor was at least 95% pure (Fig. S2). Melting points were
measured using a Reichert-Jung Thermovar hot-stage microscope
apparatus.2.6. Determination of kinetic parameters and the inhibition
constant
The activity of b-lactamase TEM-171 against CENTA, a chro-
mogenic substrate based on cephalothin, was measured in
50 mM sodium phosphate buffer, pH 7.0 at 25 C using a Shi-
madzu UV-1602 spectrophotometer. CENTA was prepared as
stock solution of 5 mM in 50 mM sodium phosphate buffer, pH
7.0. The total volume of the enzyme assay was 1 ml. The hydro-
lysis of CENTA was monitored by continuous recording of the
absorbance at 405 nm (Dε405 ¼ 6400M1cm1) [23]. The con-
centration of b-lactamase TEM-171 in the assay was 0.012 mM.
The reaction was initiated by adding CENTA at concentrations of
10, 20, 50, 100 and 200 mM to the solution containing the enzyme.
The measurements were made in triplicate. Concentrated in-
hibitor solution (4 mM) was prepared by dissolving PA-34 in
DMSO. The assay was performed in 50 mM sodium phosphate
buffer, pH 7.0 at 25 C, with the ﬁnal concentration of DMSO of
2.5%. The total volume of the inhibition assay was 1 ml. The
enzyme was added to the inhibitor solution. The reaction was
initiated as described above.
Apparent Michaelis constants (KMapp) and Vmax were deter-
mined using a weighted LineweavereBurk linearisation. The
weights were taken as V04/s2(V0). The inhibition constant KI was
determined using the weighted linearised dependence of the
derived KMapp values on the inhibitor concentration I0 according to
eq. (1). The weights for KMapp were set to the inverse of the squares
of their estimated standard deviations.KMapp ¼ KM

1þ ½I0
KI

(1)
2.7. ATR-FTIR spectroscopy for binding studies of PA-34
Attenuated total reﬂection Fourier transform infra-red (ATR-
FTIR) spectra were recorded using a Bruker Tensor 27 spectrometer
equipped with a liquid nitrogen cooled mercury cadmium telluride
detector. An aliquot of 40 ml of the sample was placed in a Bruker
thermostated (22 C) cell BioATR-II with ZnSe ATR-element. The
FTIR spectrometer was purged with a constant ﬂow of dry air. In
order to prevent minor contamination of spectra we washed ATR-
crystal in the following sequence: water, sodium dodecyl sul-
phate, water, isopropanol, water again and dried with a dry airﬂow.
As a control of the chamber clearness, a water spectrum was
registered and compared to the etalon. ATR-FTIR spectra were ac-
quired from 900 to 4000 cm1 with 1 cm1 spectral resolution. For
each spectrum,100 scans were accumulated at the 20 kHz scanning
speed and averaged. Concentrations of b-lactamase TEM-171 and
the PA-34 inhibitor were 35 mM and 100 mM, respectively. All
measurements were performed against their respective back-
ground: for TEM-171 - 50 mM phosphate buffer at pH 7.0; for the
PA-34 inhibitor - the same buffer with the addition of 2.5% DMSO.
For the enzyme-inhibitor complex, two backgrounds were
measured - 50 mM phosphate buffer at pH 7.0, 2.5% DMSO with
1 mg/ml (35 mM) b-lactamase TEM-171 to study the inhibitor state,
and the same buffer with 2.5% DMSO and 100 mM PA-34 to study
the protein state. Spectral data were processed using the Bruker
software system Opus 7.5 which includes linear blank subtraction,
straight-line baseline correction and atmospere compensation.
Where necessary, seven- or nine-point Savitsky-Golay smoothing
was used to remove white noise [24]. Peaks were identiﬁed by a
standard Bruker peak-picking procedure.
2.8. Fluorescence quenching for binding of PA-34
The measurements were performed in a triangle quartz cuvette
(1 ml) with a 10 nm slit width using a Perkin-Elmer LS 50B Fluo-
rescence Spectrometer in 10mMTris/HCl, pH 7.5, containing 80mM
NaCl at 25 C. The concentrations of TEM-171 and PA-34 inhibitor
were 35 mM and 100 mM, respectively. The spectra were recorded in
the 300e400 nm range at the excitation wavelengths of 280 nm
and 295 nm. Fluorescence SpectraViewer was used for data visu-
alisation and analysis (https://www.thermoﬁsher.com/ru/ru/
home/life-science/cell-analysis/labeling-chemistry/ﬂuorescence-
spectraviewer.html).
2.9. Molecular docking of PA-34
The crystal structure of the wild-type b-lactamase TEM-1
determined at 1.9 Å resolution (PDB ID 1xpb [25]) was used for
molecular docking studies. The 3D coordinates of PA-34 were taken
from the ChemBridge online chemical store (ID 7030665), andwere
subject to further energy-minimisation using OpenBabel [26]. The
molecular docking was done using AutoDockVina [27]. PDBQT ﬁles
for ligand and protein were generated using AutoDock tools [28].
3. Results and discussion
3.1. Production of recombinant b-lactamaseTEM-171
To probe the biological activity of inhibitors identiﬁed with the
ViCi software we used b-lactamase TEM-171 as a model enzyme. It
Fig. 2. Conformational alignment of the closest search ligand FTA and the novel non-b-
lactam inhibitor PA-34.
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substitution, Val84Ile. This substitution has no apparent effect on
the catalytic properties, which are similar for both the TEM-1 and
TEM-171 enzymes, as shown earlier [20]. We therefore hypothesise
that the conformations of the active site and the reaction proton
transfer pathway are very similar.
TEM-type b-lactamases contain one disulphide bridge con-
necting Cys77 and Cys123 residues. To promote the correct for-
mation of this disulphide bond, periplasmic protein expressionwas
chosen for the production of recombinant b-lactamase TEM-171 in
E.coli, using the pET-bla expression vector that encodes the full-
length protein with an N-terminal signal sequence [20]. The total
expression level was about 50% of the total protein content. The
double bands on the electrophoresis gels indicated the presence of
unprocessed (31.5 kDa) and processed b-lactamase TEM-171
(28.9 kDa) in the total bacterial homogenate (Fig. 1A).
Periplasmic fraction, isolated using osmotic shock, contains only
the processed form of b-lactamase TEM-171 (Fig. 1A), indicating
correct processing of the signal peptide upon translocation into the
periplasm. After subsequent anion-exchange chromatography ac-
cording to [20], the protein was further puriﬁed using size-
exclusion chromatography resulting in the estimated purity of the
protein of more than 99%. In addition, an increase of the induction-
cultivation time to 50 h at 21 C allowed for increasing the yield
signiﬁcantly, to approximately 100 mg of pure protein from 500 ml
of the E. coli culture (Fig. 1B).3.2. Lead discovery and enzyme inhibition with PA-34
In this study we aimed at identiﬁcation of a new non-b-lactam
inhibitor, which targets either the active or any other binding site of
b-lactamases. For this we used a number of non-b-lactam inhibitors
as templates. Several newly identiﬁed compounds showed stronger
inhibition of the b-lactamase TEM-171 activity compared to the
search templates. The selected compound PA-34 is structurally
similar to the template inhibitor FTA (Fig. 2 and Table 1) and be-
longs to the acylated phenoxyaniline group, which is for the ﬁrst
time described in terms of its anti-b-lactamase activity.
Both the PA-34 and the FTA compounds contain a biaryl frag-
ment. However, in PA-34 this fragment contains chlorine atoms in
ortho- and para-positions while FTA contains an unsubstituted
benzene ring. In addition, PA-34 has a carboxyl group at the end of
the carbon chain that may be important for binding to the enzyme
and its about ﬁve times stronger inhibition compared to FTA.
Table 1 also presents some other non-b-lactam structures whichFig. 1. SDS-PAGE of recombinant b-lactamase TEM-171. Panel A: lanes 1 and 2 eE.coli cell lys
lane 4 e molecular weight standards. Panel B: size-exclusion chromatography: lane 1 e po
after size-exclusion chromatography.target the active site and exhibit inhibition activity against class A
b-lactamases including boronic acid, phosphonate derivatives and a
cyclic peptide.
The kinetic measurements of the inhibition with PA-34 indicate
that upon a variation of the concentration of the inhibitor, the
values of apparent KMapp change, while the Vm values stay the same
(Fig. 3). This is in accordance with the common mechanistic
interpretation of a competitive inhibition. From the linear ﬁt ac-
cording to eq. (1) the derived values of KM and Ki are 31.5 ± 1.8 and
88 ± 10 mM, respectively (Fig. S3). Some increase in the derived KM
value compared to the one published earlier [20] may be related to
the presence of 2.5% DMSO in the buffer. This supports the hy-
pothesis that PA-34 binds to the TEM-171 enzyme in the ratio 1:1 in
a competitive and reversible manner.3.3. ATR-FTIR spectroscopy analysis
To characterise the formation of the protein-inhibitor complex
we performed ATR-FTIR spectroscopy measurements. According to
the equality of location, intensity and structure of bands amide I
(1640 cm1) and amide II (1550 cm1) in the spectra of protein
before and after inhibitor binding (data not shown), we suggest
that the binding of the inhibitor does not signiﬁcantly change the
protein state - covalent and non-covalent bonds, degree of hydra-
tion, microenvironment and the overall conformation.
According to the literature [32e34], the main absorption bands
in the spectra (Fig. 4) can be related to functional groups. The most
intensive bands correspond to the oscillations of the aromatic
skeleton: C]C (1600e1500 cm1) and CeC (1500-1450 cm1)
which are sensitive to stacking interactions with aromatic ligands
[35]. Bands of the carbonyl group (1600e1700 cm1), the carboxylate before and after the induction with IPTG, respectively; lane 3 e periplasmic fraction;
oled anion-exchange lactamase fractions; lanes 2e9 - b-lactamase containing fractions
Table 1
Structures and inhibition constants of non-b-lactam inhibitors.
Compound Structure Ki, mM
PA-34, 4-oxo-4-((4-(2,4-dichlorophenoxy)phenyl)amino)butanoic acid 90 ± 12
FTA, 3-(4-phenylamino-phenylamino)-2-(1H-tetrazol-5-yl)-acrylonitrile)
[18]
490 ± 40
Boronic acid meta-carboxyphenyl cephalosporin analog [16,29] 3.9 ± 0.51
Phosphonates [30] 76 ± 6
0.32 ± 0.04
2.00 þ 0.18
190 ± 20
0.08 ± 0.01
0.31 þ 0.04
1.47 ± 0.06
41 ± 9
Cyclic peptide, Pep90 [31] CysTyrHisPheLeuTrpGlyProCys 333 ± 13
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1350 cm1) and CeOeC (1098 cm1) are sensitive to the formation
of hydrogen bonds.
The binding of PA-34 leads to signiﬁcant changes in the spec-
trum, and a considerable decrease in the intensity is observed
(Fig. 4). We exclude a number of possible factors, which could have
affected the intensity of the spectra as follows. Speciﬁcally, the
measurements chamber was tidied and, as a control of the chamberclearness, we recorded the water spectrum, which was identical to
the etalon. We can also exclude possible variations of protein and
inhibitor concentrations, as all working solutions were prepared
from the appropriate stock solutions in a same manner and the
experiments were repeated in triplicate. Finally, we can exclude
possible changes of the extinction coefﬁcient due to the fact that
each spectrum was registered with 100 scans. Therefore, we pro-
pose that the decrease of the intensity is caused by the changes of
Fig. 3. LineweavereBurk representation of the dependence of the initial rate of CENTA
hydrolysis by the recombinant b-lactamase TEM-171. The inhibitor PA-34 is present in
the following concentrations: 1e0 mM; 2e20 mM; 3e50 mM; 4e75 mM; 5e100 mM;
6e150 mM. The concentrations of the enzyme and the substrate are as described in
section 2.6.
Fig. 4. ATR-FTIR spectra of the inhibitor alone (1, blue) and the protein-inhibitor
complex (2, pink). The concentrations of the enzyme and the inhibitor are given in
section 2.7. The main peak positions are indicated by the arrows.
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the protein-inhibitor complex. The most dramatic changes were
observed for carboxyl group bands (1256 and 1237 cm1 e80% and
76% consequently), CeOeC band (1098 cm1, 67%) and CeC aro-
matic bands (1505 and 1474 cm1, 60 and 67% respectively)
(Table 2).Table 2
Intensity of the main absorption bands in the ATR-FTIR spectrum of protein-inhibitor co
Functional group Peak position, cm1 Peak intensity, a.u., inhibitor
COOe 1560 0.0012
C]C ar 1537 0.0014
CeC ar 1505 0.0022
CeC ar 1474 0.0024
CeO COOe 1256 0.0015
CeO COOe 1237 0.0014
CeOeC 1098 0.0009We propose that the observed changes in the spectra are likely
caused by possible stacking interactions of an aromatic ring of the
inhibitor with an aromatic protein residue. Tyr105 located at the
entrance to the enzyme active site could be regarded as a candidate
for such interaction, and this is discussed further in the text. Ex-
amples of stacking protein-ligand interaction have been published
for other complexes both with biomolecules [35] and small organic
molecules [36]. Stacking interactions affect the microenvironment
and may cause changes in IR spectra, including a decrease of
intensities of some peaks. According to Malevsky [36] and Bren-
del [37], changes in the intensity of some peaks depend on a
dissociation constant of the stacking complex.
Also interesting is the reduction of the intensity for the peaks
corresponding to the CeC bond of the aromatic skeleton and the
CeOeC bond which links two rings in the PA-34 inhibitor; this may
also indicate an interaction of the aromatic skeleton of the inhibitor
with the protein.
3.4. Fluorescence quenching measurements
In order to characterise the complex formation of PA-34 and b-
lactamase TEM-171 in more detail, we performed ﬂuorescence
quenching experiments. Themethod uses the intrinsic ﬂuorescence
of the aromatic amino acids tryptophan, which is excited at 280 nm
and tyrosine, excited at 295 nm [38]. b-Lactamase TEM-171 has four
tryptophan residues (165, 210, 229, 290) and four tyrosines (46, 97,
105, 264) according to Ambler numbering [8]. Their ﬂuorescence
properties could be affected upon binding of PA-34. We have
observed for the enzyme-inhibitor complex a ﬂuorescence
quenching of 10% at 295 nm and 26% at 280 nm (Fig. 5). The higher
quenching at 280 nm suggests that the potential binding site of PA-
34 may be located close to a tyrosine residue.
In the b-lactamase TEM-1 structure (PDB ID 1xpb) only Trp165
and Tyr105 are located on the surface and are therefore potentially
accessible to ligand binding, while the other tryptophan and tyro-
sine residues are buried in the protein. We therefore propose that
the binding site of PA-34 occurs in the vicinity of Tyr105, close to
the active site. This conclusion may seem surprising, since the re-
ported binding place of a structurally similar inhibitor FTA, located
16 Å from the active site, has a different structural environment
with no obvious stacking interactions [18].
The competitive type of PA-34 inhibition observed in our kinetic
study, together with the data on ATR-FTIR and ﬂuorescence
quenching spectroscopy, albeit indirectly, suggests that PA-34 is
most likely not targeting the FTA allosteric site, but may compete
with the substrate at the entrance to the active centre. This
conclusion is also in line with ﬁve times stronger inhibition of PA-
34 compared to FTA.
3.5. Proposed ligand binding mode
To elucidate the ligand binding mode and the inhibition
mechanismwe carried out molecular docking of PA-34 into protein
binding sites. Horn and Shoichet have shown that FTA and CBTmplex.
Peak intensity, a.u. protein-inhibitor complex Intensity reduction (%)
0.0011 8.3
0.0008 41.6
0.0009 59.8
0.0008 66.7
0.0003 80.0
0.0003 75.7
0.0003 66.7
Fig. 5. Fluorescence quenching spectra recorded for b-lactamase TEM-171 and PA-34
inhibitor. The excitation wavelengths are indicated. The concentrations of the
enzyme and the inhibitor are given in section 2.8.
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steric site [18]. Therefore, we docked PA-34 to both the active and
the allosteric sites of the 1xpb crystal structure of the wild-type b-
lactamase TEM-1. The single mutation, Val84Ile, between TEM-1
and TEM-171 sequences, is located on the protein surface and is
about 20 Å away from the catalytic Ser70 OH group. The mutated
side chain is even farther away, more than 30 Å, from the allosteric
site. In addition, as noted above, this mutation does not affect the
enzyme kinetic properties.
The docking of PA-34 to the allosteric site of the protein could
possibly occur if the two helices (residues 218e224 and 274e285)
are moved away. Indeed, while in the complex with FTA the
shortest distance between these helices is about 8 Å, in the native
structure of TEM-1, used here for the docking studies, these helicesFig. 6. Docking of PA-34 to the blactamase TEM-1 active site. (A) the lowesteenergy doc
negative potential in red, neutral in white and positive potential in blue. (B) proposed in
produced with UCSF Chimera package [39].are too close to each other, thus this allosteric binding site is not
accessible.
The docking to the protein active site suggests that the binding
of PA-34 is governed by the stacking interactions between the
dichlorophenoxy ring of the inhibitor and the aromatic ring of the
Tyr105 residue (Fig. 6A). Three hydrogen bonds may be important
for the stabilisation of this complex (Fig. 6B). Arg275 NH2 and the
main chain amide of Gly242 form hydrogen bonds to the COOH
group of the inhibitor. The oxygen atom connecting two aromatic
rings in PA-34 forms the third hydrogen bond to Asn132 ND2. An
interesting feature of the inhibitor binding is a possible formation
of a halogen bond between the ligand chlorine atom in the ortho-
position and the hydroxyl group of Ser70 with the CleO distance
of 3.4 Å.
This putative binding mode of PA-34 with b-lactamase TEM-171
is in agreement with the observed changes in the intensity of the
absorption bands in the IR spectrum during complex formation
(Table 2). The intensity of the absorption bands of the carbon atoms
in the aromatic rings is reduced by 60%. The observed reduction of
the absorption of CeOeC and the carboxyl group of the inhibitor in
the IR spectrum can be explained by the hydrogen bonds to Arg275,
Gly242 and Asn132. We propose that PA-34 acts as an inhibitor by
simply blocking the access to the active site as it binds. The fact that
PA-34 binds with ﬁve times higher afﬁnity compared to FTA could
be a reﬂection of speciﬁc interactions between this ligand and the
residues located in its binding site. We suggest that PA-34 binds to
the entrance of the enzyme active site, hampering the substrate
from access to the catalytic Ser70; this fact may account for Ki being
somewhat lower compared to other active site inhibitors (Table 1).
Sequence alignment shows that Gly242 is conserved among all
b-lactamases of molecular class A, involving penicillinases, cepha-
losporinases, and carbapenemases (TEM, SHV, CTX-M, KPC), and
Tyr105 is conserved among all major types of molecular class A b-
lactamases (TEM, SHV, CTX-M). Thus, according to the proposed
binding mode, the PA-34 inhibitor is coordinated by at least twoking model of PA-34; the protein is shown as electrostatic potential surface with the
teractions of PA-34. The hydrogen bonds are shown as dashed lines. This ﬁgure was
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compound can show an inhibitory activity for many clinically
relevant b-lactamases of molecular class A.
With this inmind, crystal structures of the enzyme-bound ligands
are being sought in order to conﬁrm the proposed binding mode and
provide an accurate description of the conformation of the ligand.
Site-directedmutagenesis of the residues of interest (Tyr105, Asn132,
Gly242 and Arg275) and chemical modiﬁcation of the inhibitor itself
may also be attempted to illustrate the inhibition mechanism and
improve inhibition potency by a rational design approach.
4. Conclusions
Inhibitors of b-lactamases have been co-administered with b-
lactam antibiotics for a number of years, and normally this has
improved therapeutic effects. The majority of these inhibitors are
themselves b-lactams, with many of them being derived from mi-
crobial natural products. Their presence in the biosphere for many
years indicates that enzymes, which are naturally resistant to them,
may have already evolved. Even if not, the development of resistant
species may require only a few mutations and may arise rapidly
upon therapeutic use. Due to the great diversity of b-lactamases
and their widespread danger, there is a pressing need for novel b-
lactamases inhibitors, preferably those which are not based on the
established b-lactam paradigm.
We have shown the promise of an approach to ﬁnding new
potential inhibitors of TEM type b-lactamases with scaffolds
distinct from b-lactam-based compounds. The identiﬁed inhibitor
PA-34 has higher afﬁnity to b-lactamase than the initial search
templates. Moreover, the obtained data suggest a new binding
modee blocking access to the active sitee thatmay be of particular
interest to a search of stable and widely applicable inhibitors. We
propose that binding of the PA-34 inhibitor is assisted by at least
two highly conserved residues: Gly242 and the Tyr105. We also
propose that the PA-34 compound may be regarded as a potential
inhibitor of many clinically relevant b-lactamases of molecular class
A. Crystallographic and rational design studies are required to
further improve the inhibition power.
There is an increasing number of new drug candidates exhibit-
ing poor solubility in water, which hinders their therapeutic ap-
plications. The approaches for solubility enhancement include solid
dispersions, chemical modiﬁcations, a use of surfactants, etc. [40].
Unknown speciﬁcity and toxicity of potential drug candidates may
present additional challenges and require the use of advanced drug
delivery methods and extensive in silico-made predictions.
Although we do not yet have the data about the inhibitory po-
wer of PA-34 on other b-lactamases, our results open up new op-
portunities in a search of broad-spectrum inhibitors based on the
scaffold found, which in turn may help in combating antibiotic
resistance more efﬁciently.
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